Summit Therapeutics Inc. Payments of Debt Issuance Costs
Summit Therapeutics Inc. (SMMT) reported Payments of Debt Issuance Costs of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2025-02-24
- Summit Therapeutics Inc. payments of debt issuance costs for the quarter ending 2022-12-31 was $44.00K.
- Summit Therapeutics Inc. payments of debt issuance costs for the quarter ending 2022-09-30 was $0.00.
- Summit Therapeutics Inc. payments of debt issuance costs for the quarter ending 2021-12-31 was $0.00.
- Summit Therapeutics Inc. payments of debt issuance costs for the quarter ending 2021-09-30 was $0.00.
- Summit Therapeutics Inc. payments of debt issuance costs for fiscal 2024 was $0.00.
- Summit Therapeutics Inc. payments of debt issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Summit Therapeutics Inc. payments of debt issuance costs for fiscal 2022 was $44.00K, a 18.52% decline from fiscal 2021.
- Summit Therapeutics Inc. payments of debt issuance costs for fiscal 2021 was $54.00K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-24 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-24 | |||
| 2022-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $44.00K derived: sum of 2 quarters · filed 2025-02-24 | $44.00K 10-K · filed 2025-02-24 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $54.00K 10-K · filed 2023-03-09 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $54.00K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $54.00K 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $0.00 derived: sum of 2 quarters · filed 2022-12-21 | $0.00 10-K/A · filed 2022-12-21 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |